摘要
磷代谢紊乱是慢性肾脏病(CKD)病人常见的并发症之一,当肾小球滤过率(eGFR)的下降至30 mL·min-1·1.73 m-2,处于CKD的4、5期时,肾脏排磷障碍不能代偿时,将导致长期高磷血症;而高磷血症可能是CKD病人除了高血脂、高血压、高血糖等传统危险因素外,导致动脉粥样硬化性疾病的新型危险因素,且动脉粥样硬化性心脑血管疾病是CKD病人的首要死亡原因,但目前高磷血症导致动脉粥样硬化(AS)的机制目前尚未明确,本研究将对CKD病人高磷血症与动脉粥样硬化相关性的认识进展进行综述。
phosphorus metabolism disorder is one of the common complications in patients with chronic kidney disease(CKD),when the Glomerular filtration rate(eGFR)down to 30 mL/(min·1.73 m~2),and is in the stage 4-5 of CKD,if the renal phosphorus discharge disorder cannot be compensated,it will lead to long-term hyperphosphatemia.and hyperphosphatemia is likely to be in patients with chronic kidney disease in addition to the traditional risk factors such as hyperlipidemia,hypertention,hyperglycemia,lead to a new risk factor for atherosclerotic disease.Atherosclerotic cardiovascular and cerebrovascular disease are the primary cause of death for patients with CKD.However,the mechanism of hyperphosphatemia causing atherosclerosis(AS)has not been clear,this study will focus on hyperphosphatemia for CKD patients with article to describes some advances in the understanding of the relevance of atherosclerosis.
作者
董云萍
李玉凤
蒋红樱
李静
李洛华
DONG Yunping;LI Yufeng;JIANG Hongying;LI Jing;LI Luohua(Department of Nephrology,The Second Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650101,China)
出处
《安徽医药》
CAS
2021年第1期1-3,共3页
Anhui Medical and Pharmaceutical Journal
基金
云南省科技计划项目[2017FE468(⁃202)]。